Earlier need of infliximab intensification in ulcerative colitis than in Crohn's disease

J Crohns Colitis. 2014 Oct;8(10):1331-2. doi: 10.1016/j.crohns.2014.03.007. Epub 2014 Mar 29.

Authors

Fernando Magro¹, Eduardo Rodrigues-Pinto², Susana Lopes², Guilherme Macedo²

Affiliations

¹ Gastroenterology Department, Centro Hospitalar São João, Porto, Portugal; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Portugal; MedInUP - Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal. Electronic address: fm@med.up.pt.
² Gastroenterology Department, Centro Hospitalar São João, Porto, Portugal.

PMID: 24690137
DOI: 10.1016/j.crohns.2014.03.007

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Colitis, Ulcerative / drug therapy*
Crohn Disease / drug therapy*
Drug Tolerance
Follow-Up Studies
Humans
Infliximab
Retrospective Studies
Time Factors
Young Adult

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Infliximab